FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317892015> ?p ?o ?g. }

• W4317892015 endingPage "606" @default.
• W4317892015 startingPage "606" @default.
• W4317892015 abstract "606 Background: Despite the improved outcome achieved by the addition of the anti-PD-L1 durvalumab to standard chemotherapy, the vast majority of BTC do not benefit from chemo-immunotherapy. Immunosuppressive microenvironment is a dominant feature of BTC, involved in tumour progression and drug resistance. Here, we investigated the biological role and treatment implications of the adenosine-producing enzyme CD73 in a clinically-annotated cohort of BTC. CD73, an ecto-5’-nucleotidase (NT5E), creates an immunosuppressive tumour-promoting microenvironment by converting ATP to adenosine. Methods: Immunohistochemistry for CD73, CD4/CD8 and FOXP3 as well as whole-exome and transcriptomic sequencing were performed on resected specimens of 80 BTC (Illumina Platform). Spatial Transcriptomics was performed by using Visium Spatial Gene Expression-10x Genomics). Silencing of CD73 was obtained by transient transfection od CD73-siRNA, while genetic Knock-out by using CRISPR-Cas system technology in two BTC cell lines. Tumor growth was assessed in 2D and in 3D cell culture by using MTS assay and spheroid growth analysis before and after treatment with selected drugs. Statistical and Survival, correlation analyses were performed. Results: High CD73 expression (CD73 high ) was associated with older age (>70 years, p=0.01), gallbladder subsite (p=0.03), and nodal involvement (p=0.04). CD73 high tumours were significantly enriched in infiltrating FOXP3+ T lymphocytes (p<0.001). CD73 high status was independent predictor of poorer prognosis at the multivariate analysis (p=0,03) together with ECOG PS ≥2 (p=0,001) and the pathological stage (p=0,025) and was associated with a remarkably shorter RFS in patients treated with adjuvant chemotherapy (p=0,011). At the transcriptomic level, CD73 high tumours were significantly enriched in upregulated EMT, TNF-alfa/NFKB, hypoxia and G2/M checkpoint signaling pathways and p53, BMI1, MEL18, EGFR and K-RAS genes. In in vitro models, siRNA-mediated depletion and CRISPR-CAS9 gene KO of CD73 sensitized both BTC 2D and 3D culture to cisplatin/gemcitabine treatment. The pharmacological inhibition of CD73 by AMCP improved the sensitivity of BTC cell lines to cisplatin/gemcitabine treatment. Finally, Spatially resolved transcriptomics of CD73 high revealed a critical role of CD73 in tumor immunity and therapeutic response. Conclusions: We showed that CD73 high BTC display aggressive biological features, poorer prognosis and resistance to standard chemotherapy. The therapeutic targeting of this adenosinergic ectonucleotidase by clinically-available compounds has the potential to enhance the efficacy of conventional treatment in BTC." @default.
• W4317892015 created "2023-01-25" @default.
• W4317892015 creator A5000225240 @default.
• W4317892015 creator A5003750614 @default.
• W4317892015 creator A5017669867 @default.
• W4317892015 creator A5024297816 @default.
• W4317892015 creator A5026433226 @default.
• W4317892015 creator A5032330087 @default.
• W4317892015 creator A5037705070 @default.
• W4317892015 creator A5037883227 @default.
• W4317892015 creator A5038322549 @default.
• W4317892015 creator A5045317205 @default.
• W4317892015 creator A5052998358 @default.
• W4317892015 creator A5061222063 @default.
• W4317892015 creator A5065532659 @default.
• W4317892015 creator A5066004697 @default.
• W4317892015 creator A5075073321 @default.
• W4317892015 creator A5075865584 @default.
• W4317892015 creator A5081648394 @default.
• W4317892015 creator A5081955195 @default.
• W4317892015 creator A5086592733 @default.
• W4317892015 creator A5088593159 @default.
• W4317892015 date "2023-02-01" @default.
• W4317892015 modified "2023-09-27" @default.
• W4317892015 title "Integrated analysis of genomic and transcriptomic profiles to examine CD73/NT5E as a driver of drug-resistance and immunosuppression in biliary cancer (BTC)." @default.
• W4317892015 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.606" @default.
• W4317892015 hasPublicationYear "2023" @default.
• W4317892015 type Work @default.
• W4317892015 citedByCount "0" @default.
• W4317892015 crossrefType "journal-article" @default.
• W4317892015 hasAuthorship W4317892015A5000225240 @default.
• W4317892015 hasAuthorship W4317892015A5003750614 @default.
• W4317892015 hasAuthorship W4317892015A5017669867 @default.
• W4317892015 hasAuthorship W4317892015A5024297816 @default.
• W4317892015 hasAuthorship W4317892015A5026433226 @default.
• W4317892015 hasAuthorship W4317892015A5032330087 @default.
• W4317892015 hasAuthorship W4317892015A5037705070 @default.
• W4317892015 hasAuthorship W4317892015A5037883227 @default.
• W4317892015 hasAuthorship W4317892015A5038322549 @default.
• W4317892015 hasAuthorship W4317892015A5045317205 @default.
• W4317892015 hasAuthorship W4317892015A5052998358 @default.
• W4317892015 hasAuthorship W4317892015A5061222063 @default.
• W4317892015 hasAuthorship W4317892015A5065532659 @default.
• W4317892015 hasAuthorship W4317892015A5066004697 @default.
• W4317892015 hasAuthorship W4317892015A5075073321 @default.
• W4317892015 hasAuthorship W4317892015A5075865584 @default.
• W4317892015 hasAuthorship W4317892015A5081648394 @default.
• W4317892015 hasAuthorship W4317892015A5081955195 @default.
• W4317892015 hasAuthorship W4317892015A5086592733 @default.
• W4317892015 hasAuthorship W4317892015A5088593159 @default.
• W4317892015 hasConcept C104317684 @default.
• W4317892015 hasConcept C121608353 @default.
• W4317892015 hasConcept C126322002 @default.
• W4317892015 hasConcept C150194340 @default.
• W4317892015 hasConcept C162317418 @default.
• W4317892015 hasConcept C2776107976 @default.
• W4317892015 hasConcept C2776534502 @default.
• W4317892015 hasConcept C2777701055 @default.
• W4317892015 hasConcept C502942594 @default.
• W4317892015 hasConcept C55493867 @default.
• W4317892015 hasConcept C71924100 @default.
• W4317892015 hasConcept C86803240 @default.
• W4317892015 hasConceptScore W4317892015C104317684 @default.
• W4317892015 hasConceptScore W4317892015C121608353 @default.
• W4317892015 hasConceptScore W4317892015C126322002 @default.
• W4317892015 hasConceptScore W4317892015C150194340 @default.
• W4317892015 hasConceptScore W4317892015C162317418 @default.
• W4317892015 hasConceptScore W4317892015C2776107976 @default.
• W4317892015 hasConceptScore W4317892015C2776534502 @default.
• W4317892015 hasConceptScore W4317892015C2777701055 @default.
• W4317892015 hasConceptScore W4317892015C502942594 @default.
• W4317892015 hasConceptScore W4317892015C55493867 @default.
• W4317892015 hasConceptScore W4317892015C71924100 @default.
• W4317892015 hasConceptScore W4317892015C86803240 @default.
• W4317892015 hasIssue "4_suppl" @default.
• W4317892015 hasLocation W43178920151 @default.
• W4317892015 hasOpenAccess W4317892015 @default.
• W4317892015 hasPrimaryLocation W43178920151 @default.
• W4317892015 hasRelatedWork W1861033863 @default.
• W4317892015 hasRelatedWork W2178868239 @default.
• W4317892015 hasRelatedWork W2553442423 @default.
• W4317892015 hasRelatedWork W2771066073 @default.
• W4317892015 hasRelatedWork W3123929348 @default.
• W4317892015 hasRelatedWork W3195008613 @default.
• W4317892015 hasRelatedWork W3210687804 @default.
• W4317892015 hasRelatedWork W4303613753 @default.
• W4317892015 hasRelatedWork W4308769187 @default.
• W4317892015 hasRelatedWork W4312075079 @default.
• W4317892015 hasVolume "41" @default.
• W4317892015 isParatext "false" @default.
• W4317892015 isRetracted "false" @default.
• W4317892015 workType "article" @default.